Latest News & Features
article
The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment. 5 July 2022
Big Pharma
Bristol-Myers Squibb claims violations under the Hatch-Waxman Act in an attempt to shut down generic. 30 June 2022
Big Pharma
Justice Mellor was unconvinced by arguments that Teva could have cleared the way. 30 June 2022
article
Many jurisdictions provide patent term extensions or Supplementary Protection Certificates in recognition of the fact that the time taken to achieve regulatory approval for patented products can often delay their release into the market. 30 June 2022
Big Pharma
Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement. 28 June 2022
Americas
Drugmaker Genus Lifesciences and pharmaceutical company Mallinckrodt have agreed to settle their trade secret dispute related to a cocaine hydrochloride formulation. 28 June 2022
Big Pharma
India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film. 27 June 2022
Big Pharma
The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity. 23 June 2022
Big Pharma
The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug. 23 June 2022
Big Pharma
The European Commission has opened an antitrust investigation to assess whether Switzerland-headquartered Vifor Pharma has engaged in anticompetitive conduct. 21 June 2022